Kangchen Pharmaceutical\'s announcement on the appointment of Chief Financial Officer
Beijing Kangchen Pharmaceutical Co., Ltd. Accountant Service Selection and Employment System
Announcement of Resignation of Senior Management Personnel from Beijing Konruns Pharmaceutical
Announcement from Beijing Konruns Pharmaceutical on traditional Chinese medicine innovative drug ZY5301 clinical research results being featured in the sub-journal of JAMA.
Announcement on the Change of Continuous Supervision and Sponsorship Representative of Beijing Konruns Pharmaceutical
Announcement on the signing of house rental contract and related trade of Beijing Konruns Pharmaceutical
Kangchen Pharmaceutical's announcement on being certified as the 8th batch of national manufacturing individual champion enterprises
Announcement of Resolutions of Kangchen Pharmaceutical's 2023 Annual General Meeting of Shareholders
Legal Opinion of Beijing Guofeng Law Firm on the 2023 Annual General Meeting of Shareholders of Beijing Kangchen Pharmaceutical Co., Ltd.
Kangchen Pharmaceutical's 2023 Annual General Meeting of Shareholders Meeting Materials
Kangchen Pharmaceutical's announcement on preparation for asset impairment in 2023
Kangchen Pharmaceutical's announcement on the completion of the 2023 annual performance commitment for Beijing Kangchen Biotechnology Co., Ltd.'s secret interest rate cover business
Kangchen Pharmaceutical's Notice on Convening the 2023 Annual General Meeting of Shareholders
Kangchen Pharmaceutical 2023 Internal Control Evaluation Report
Kangchen Pharmaceutical's 2023 Audit Committee Performance Report
Special Report on the 2023 Independent Directors' Independence Self-Inspection
Report on the evaluation of the performance of Huaxing Certified Public Accountants (Special General Partnership) by Beijing Kangchen Pharmaceutical Co., Ltd.
Report of the Audit Committee of the Board of Directors on the performance of supervisory duties by Huaxing Certified Public Accountants (Special General Partnership)
Kangchen Pharmaceutical's announcement that the Phase III clinical trial of Jincao tablets, a Class 1.2 innovative traditional Chinese medicine, has reached the main research end
Announcement of Resolutions of Kangchen Pharmaceutical's 2024 First Extraordinary General Meeting of Shareholders
No Data
No Data